News

Jennifer Martin, PhD, AASM board of directors' member and professor of medicine at UCLA discussed CBI-T and some of the challenges in treating patients with chronic insomnia.

Researchers also found that patients treated with autologous hematopoietic stem cell transplantation had higher rates of infection then other DMT-treated groups.

The director of the Montefiore Headache Center discussed the impact of halving headache days for patients with migraine.

The duo from Vanderbilt University discussed the lack of awareness for functional seizures, their differences in treatment, and what needs to change about their current management.

Alector’s announcement about the INVOKE-2 study follows a similar update regarding its INFRONT-3 study for frontotemporal dementia.

A roundtable discussion featuring Scott Perry, MD, Orrin Devinsky, MD, and Tracy Salazar, PhD, details how advocacy organizations can help guide patients with epilepsy and their caregivers with a seizure action plan.

Patients who had a mobile stroke unit dispatched had lower 3-month coprimary disability score.

The DMD treatment pipeline boasts a number of therapeutics with varying mechanisms of action and delivery systems, pointing to a promising future for treatment.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.

The calcium, magnesium, potassium, and sodium oxybates solution, marketed as Xywav, was approved for cataplexy and daytime sleepiness in narcolepsy in July 2020.

The neurologist from Cleveland Clinic discussed how patients with early-onset NMOSD were more likely to have severe residual vision loss.

The Biomodex-developed models have also been studied in pre-procedural rehearsal for brain aneurysms.

A roundtable discussion featuring Scott Perry, MD, Orrin Devinsky, MD, and Tracy Salazar, PhD, details how seizure action plans change from pediatrics to adults and the need for adjustments.

ElectroCore announced that the expanded indication, noting that gammaCore is now the only acute and preventive option approved for both adult and adolescent migraine.

The assistant professor of neurology at Thomas Jefferson University provided perspective on how researchers have gained a better understanding of using modalities in poststroke patients.

Researchers observed statistically significant improvements of the EDSS score along with a majority of patients showing no new enlarging or gadolinium-enhancing MRI lesions.

Researchers found that 93% of patients with AS exhibited dystonia in their limbs, mouth, neck, or trunk.

With promising data presented at WORLDSymposium 2021 and a PDUFA date looming in May, investigator Priya S. Kishnani, MD, offered her insight on Sanofi’s investigational therapy.

The Evelyn F. McKnight Neurocognitive Scholar at the University of Miami Miller School of Medicine discussed observing how sleep may impact cognitive decline in different populations.

Using the largest existing cEEG data set, researchers identified seizure chronotypes at multiple timescales, noting that circadian and multidien seizure cycles are equally strong and highly prevalent.

Here's what is coming soon to NeurologyLive.

The data revealed some of the more common and problematic symptoms, challenges, and comorbidities that persist for these individuals despite care.

The assistant professor of pediatric neurology at Washington University in St. Louis spoke to the results of a recent survey she and colleagues conducted.

ACI-12589 aims to become the world’s first diagnostic tool for assessing brain alpha-synuclein pathology in patients with Parkinson disease.

The chief scientific officer of the Parkinson’s Foundation discussed the state of mental health services for people with Parkinson disease during the COVID-19 pandemic.

Data presented at WORLDSymposium 2021 suggest that the Sanofi enzyme replacement therapy is effective and safe compared to the company’s other agent, alglucosidase alfa.

The AASM board of directors' member and professor of medicine at UCLA discussed the benefits of CBT-I and its efficacy compared to pharmacological treatments.

AMT-130 is uniQure’s first clinical program focusing on the central nervous system incorporating its proprietary miQURE silencing technology platform.